08:21 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

BMS reports CheckMate -142 data for Opdivo plus Yervoy in dMMR or MSI-H metastatic CRC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab plus Yervoy ipilimumab led to an objective response rate (ORR) of 55% among 119 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC)...
20:58 , Jun 1, 2017 |  BC Week In Review  |  Clinical News

BMS reports Phase I/IIa data for LAG3 mAb plus Opdivo in melanoma

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Bristol-Myers Squibb Co. (NYSE:BMY) reported data from a cohort of 31 evaluable melanoma patients who progressed on or after anti-PD-1...
23:10 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) In vitro and mouse studies suggest inhibiting LAG3 could help treat PD. In mouse primary cortical neurons treated with neurotoxic α-synuclein (SNCA) fibrils, LAG3 knockout or two anti-LAG3 mouse antibodies decreased the...
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Bristol-Myers, Ono Pharmaceutical deal

Bristol-Myers Squibb and Ono partnered to jointly develop and commercialize multiple products, including Opdivo nivolumab and Yervoy ipilimumab, in Japan, South Korea and Taiwan. The deal also includes BMS’s lirilumab ( BMS-986015; ...
23:55 , Jul 24, 2014 |  BC Extra  |  Company News

Bristol-Myers, Ono ink Asia immunotherapy deal

Bristol-Myers Squibb Co. (NYSE:BMY) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528) partnered to jointly develop and commercialize multiple products, including Opdivo nivolumab and Yervoy ipilimumab, in Japan, South Korea and Taiwan. The deal also includes early...